Cipla Gets USFDA VAI Classification for Goa Manufacturing Facility
Mumbai: Cipla Limited has announced that the United States Food and Drug Administration (USFDA) has classified the inspection conducted at its manufacturing facility in Verna, Goa, as Voluntary Action Indicated (VAI).
The inspection, which included a routine current Good Manufacturing Practices (cGMP) assessment and a Pre-Approval Inspection (PAI), was carried out between April 6 and April 17, 2026, at the company’s Goa-based manufacturing site.
According to the company’s regulatory filing dated June 11, 2026, the USFDA communicated its inspection classification on June 10, 2026. A VAI classification indicates that while certain observations may have been identified during the inspection, the agency does not recommend any regulatory or enforcement action at this stage.
The positive outcome reflects the company’s continued commitment to maintaining quality standards and regulatory compliance across its manufacturing operations.
